ES2435775T3 - Moduladores de receptor tipo Toll 3, procedimientos y usos - Google Patents

Moduladores de receptor tipo Toll 3, procedimientos y usos Download PDF

Info

Publication number
ES2435775T3
ES2435775T3 ES06846174T ES06846174T ES2435775T3 ES 2435775 T3 ES2435775 T3 ES 2435775T3 ES 06846174 T ES06846174 T ES 06846174T ES 06846174 T ES06846174 T ES 06846174T ES 2435775 T3 ES2435775 T3 ES 2435775T3
Authority
ES
Spain
Prior art keywords
antibody
seq
amino acid
cells
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06846174T
Other languages
English (en)
Spanish (es)
Inventor
Karen E. Duffy
Chong C. Huang
Roberta Lamb
Mouhamadou L. Mbow
Robert T. Sarisky
Mateo Lani San
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Centocor Ortho Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of ES2435775T3 publication Critical patent/ES2435775T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES06846174T 2005-10-27 2006-10-26 Moduladores de receptor tipo Toll 3, procedimientos y usos Active ES2435775T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73079305P 2005-10-27 2005-10-27
US730793P 2005-10-27
PCT/US2006/060305 WO2007051164A2 (en) 2005-10-27 2006-10-26 Toll like receptor 3 modulators, methods and uses

Publications (1)

Publication Number Publication Date
ES2435775T3 true ES2435775T3 (es) 2013-12-23

Family

ID=37968676

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06846174T Active ES2435775T3 (es) 2005-10-27 2006-10-26 Moduladores de receptor tipo Toll 3, procedimientos y usos

Country Status (6)

Country Link
US (1) US7718778B2 (https=)
EP (1) EP1945820B1 (https=)
JP (1) JP5199878B2 (https=)
DK (1) DK1945820T3 (https=)
ES (1) ES2435775T3 (https=)
WO (1) WO2007051164A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155889A4 (en) * 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
EP2238155A4 (en) * 2007-12-26 2011-07-06 Centocor Ortho Biotech Inc CYNOMOLGUS TYPE TOLL 3 RECEIVER
ES2360334T3 (es) * 2008-06-27 2011-06-03 Theranor Sprl Composiciones farmacéuticas de anticuerpos para enfermedades causadas por virus.
WO2010039615A2 (en) * 2008-10-03 2010-04-08 Centocor Ortho Biotech Inc. Papio cynocephalus toll-like receptor 3
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
PE20110808A1 (es) * 2008-10-31 2011-10-31 Janssen Biotech Inc Anticuerpos contra el receptor 3 de tipo toll
US20130090457A1 (en) * 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
EA021512B1 (ru) * 2009-04-29 2015-07-30 Янссен Байотек Инк. Антагонисты толл-подобного рецептора 3
ES2543095T3 (es) 2009-07-10 2015-08-14 Innate Pharma Agentes de unión a TLR3
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2012095432A2 (en) 2011-01-12 2012-07-19 Innate Pharma Tlr3 binding agents
EP2855527B1 (en) 2012-05-31 2018-08-01 Innate Pharma Tlr3 binding agents
EP3560960A1 (en) * 2013-04-22 2019-10-30 The University of Tokyo Preventive or therapeutic agent for inflammatory disease
WO2019118884A1 (en) * 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE458053T1 (de) 1997-05-07 2010-03-15 Schering Corp Menschliche toll-like-rezeptorproteine, zugehörige reagenzien und verfahren
US20030032090A1 (en) * 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
ES2298905T3 (es) * 1997-10-17 2008-05-16 Genentech, Inc. Homologos de tipo toll humanos.
ATE365043T1 (de) 1999-03-09 2007-07-15 Anker Stefan Endotoxinhemmern zur behandlung von kachexie
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7709451B2 (en) 2001-09-07 2010-05-04 Trustees Of Boston University Method and composition for treating immune complex associated disorders
WO2003031573A2 (en) 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
EP1495756A4 (en) 2002-04-08 2009-10-28 Takeda Pharmaceutical THERAPEUTIC AGENT FOR SEVERE SEPTIC STATE PREVENTION
NZ538812A (en) * 2002-08-15 2009-02-28 3M Innovative Properties Co Immunostimulatory compositions and methods of stimulating an immune response
US20050158799A1 (en) * 2003-10-17 2005-07-21 Fitzgerald Katherine A. TRIF-related adaptor molecule (TRAM) and uses thereof
AR051836A1 (es) * 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos

Also Published As

Publication number Publication date
EP1945820A2 (en) 2008-07-23
EP1945820A4 (en) 2009-02-18
WO2007051164A8 (en) 2008-06-12
EP1945820B1 (en) 2013-08-28
US7718778B2 (en) 2010-05-18
JP5199878B2 (ja) 2013-05-15
WO2007051164A3 (en) 2007-11-29
JP2009523010A (ja) 2009-06-18
DK1945820T3 (da) 2013-11-11
US20070098716A1 (en) 2007-05-03
WO2007051164A2 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
ES2435775T3 (es) Moduladores de receptor tipo Toll 3, procedimientos y usos
TWI487535B (zh) 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
JP4252061B2 (ja) 選択的ＩＦＮ−γ経路インヒビターとしてのヒト抗ＩＦＮ−γ中和抗体
ES2550099T3 (es) Antagonistas del receptor Nogo
ES2444012T3 (es) Composiciones y metodos relacionados con anticuerpos de receptores de glucagón
RU2712251C1 (ru) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
KR20200076731A (ko) 항-il23 특이적 항체로 건선성 관절염을 치료하는 안전하고 유효한 방법
CA3194384A1 (en) Caninized rat antibodies to canine interleukin-31 receptor alpha
JP2010500380A (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
US20090136509A1 (en) Use of Toll-Like Receptor 4 Antagonists for the Treatment or Prevention of Osteoarthritic Conditions
US20140255388A1 (en) Toll like receptor 3 antagonists, methods and uses
US20180244787A1 (en) Anti-human cxcr3 antibodies for treatment of vitiligo
JP2025081391A (ja) 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
JP2011507552A (ja) カニクイザルトール様受容体３
CN110300763A (zh) 用于治疗白癜风的抗人cxcr3抗体
CN101415438A (zh) Toll样受体3拮抗剂、方法和用途
CN119285769A (zh) 多特异性抗体及其医药用途
JPWO2023073615A5 (https=)
HK1131744B (en) Toll like receptor 3 antagonists, methods and uses
HK1084689B (en) Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors